Y-mAbs Therapeutics, Inc. (YMAB) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Y-mAbs Therapeutics, Inc. (YMAB) Bundle
Streamline your analysis and improve precision with our (YMAB) DCF Calculator! Equipped with real data from Y-mAbs Therapeutics, Inc. and customizable assumptions, this tool empowers you to forecast, analyze, and value (YMAB) like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 20.8 | 34.9 | 65.3 | 84.8 | 124.1 | 181.5 | 265.5 | 388.5 | 568.3 |
| Revenue Growth, % | 0 | 0 | 68.18 | 87.03 | 29.96 | 46.29 | 46.29 | 46.29 | 46.29 | 46.29 |
| EBITDA | -82.8 | -119.5 | -54.5 | -94.7 | -25.7 | -57.1 | -83.6 | -122.3 | -178.9 | -261.7 |
| EBITDA, % | 100 | -576.09 | -156.15 | -145.14 | -30.27 | -46.05 | -46.05 | -46.05 | -46.05 | -46.05 |
| Depreciation | .2 | .4 | .8 | .8 | .7 | 26.4 | 38.6 | 56.5 | 82.6 | 120.8 |
| Depreciation, % | 100 | 1.91 | 2.24 | 1.29 | 0.86655 | 21.26 | 21.26 | 21.26 | 21.26 | 21.26 |
| EBIT | -83.0 | -119.9 | -55.3 | -95.6 | -26.4 | -57.4 | -83.9 | -122.8 | -179.6 | -262.7 |
| EBIT, % | 100 | -578 | -158.39 | -146.43 | -31.13 | -46.23 | -46.23 | -46.23 | -46.23 | -46.23 |
| Total Cash | 207.1 | 114.6 | 181.6 | 105.8 | 78.6 | 122.3 | 178.9 | 261.7 | 382.8 | 560.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 7.7 | 12.5 | 22.5 | 41.6 | 60.9 | 89.1 | 130.3 | 190.7 |
| Account Receivables, % | 100 | 0 | 22.1 | 19.2 | 26.47 | 33.55 | 33.55 | 33.55 | 33.55 | 33.55 |
| Inventories | .0 | -.8 | 5.5 | 6.7 | 5.1 | 31.8 | 46.5 | 68.1 | 99.6 | 145.7 |
| Inventories, % | 100 | -3.86 | 15.8 | 10.27 | 5.97 | 25.64 | 25.64 | 25.64 | 25.64 | 25.64 |
| Accounts Payable | 8.5 | 9.4 | 13.6 | 14.2 | 6.1 | 52.8 | 77.3 | 113.1 | 165.4 | 241.9 |
| Accounts Payable, % | 100 | 45.17 | 38.83 | 21.72 | 7.14 | 42.57 | 42.57 | 42.57 | 42.57 | 42.57 |
| Capital Expenditure | -2.0 | -.2 | -1.0 | .0 | .0 | -.9 | -1.3 | -1.9 | -2.8 | -4.1 |
| Capital Expenditure, % | 100 | -0.84337 | -2.77 | 0 | 0 | -0.72288 | -0.72288 | -0.72288 | -0.72288 | -0.72288 |
| Tax Rate, % | -2.69 | -2.69 | -2.69 | -2.69 | -2.69 | -2.69 | -2.69 | -2.69 | -2.69 | -2.69 |
| EBITAT | -80.8 | -118.9 | -56.3 | -96.3 | -27.1 | -57.0 | -83.3 | -121.9 | -178.3 | -260.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -74.1 | -117.1 | -66.4 | -100.9 | -42.8 | -30.6 | -55.6 | -81.3 | -119.0 | -174.0 |
| WACC, % | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -351.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -178 | |||||||||
| Terminal Value | -3,168 | |||||||||
| Present Terminal Value | -2,196 | |||||||||
| Enterprise Value | -2,547 | |||||||||
| Net Debt | -77 | |||||||||
| Equity Value | -2,470 | |||||||||
| Diluted Shares Outstanding, MM | 44 | |||||||||
| Equity Value Per Share | -56.59 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Y-mAbs Therapeutics, Inc. (YMAB) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, market penetration, and R&D expenditures.
- Instant Valuation Calculations: Provides real-time assessments of intrinsic value, NPV, and other financial metrics.
- Industry-Leading Precision: Utilizes Y-mAbs Therapeutics' (YMAB) actual financial data for accurate valuation results.
- Effortless Scenario Planning: Easily evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Streamlines the valuation process, removing the need to develop intricate models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template featuring Y-mAbs Therapeutics, Inc. (YMAB) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly observe updated results, including Y-mAbs Therapeutics, Inc. (YMAB)'s intrinsic value.
- Step 5: Make well-informed investment choices or create reports based on the outputs.
Why Choose This Calculator for Y-mAbs Therapeutics, Inc. (YMAB)?
- Designed for Experts: A specialized tool utilized by researchers, investors, and financial analysts.
- Comprehensive Data: Y-mAbs' historical and forecasted financials integrated for precision.
- Flexible Scenario Analysis: Effortlessly model various projections and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Detailed instructions lead you seamlessly through the calculations.
Who Should Use Y-mAbs Therapeutics, Inc. (YMAB)?
- Investors: Gain insights into cutting-edge therapies and make informed investment choices.
- Healthcare Analysts: Streamline your research with comprehensive data on innovative treatments.
- Consultants: Tailor presentations and reports efficiently using our detailed market analysis.
- Biotech Enthusiasts: Expand your knowledge of the biotechnology sector with real-life case studies.
- Educators and Students: Utilize as a resource for practical learning in biotechnology and healthcare finance courses.
What the Template Contains
- Pre-Filled Data: Includes Y-mAbs Therapeutics, Inc.’s (YMAB) historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations tailored for YMAB.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs relevant to Y-mAbs.
- Key Financial Ratios: Analyze YMAB’s profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates specific to Y-mAbs Therapeutics.
- Clear Dashboard: Charts and tables summarizing key valuation results for Y-mAbs Therapeutics, Inc. (YMAB).